肺癌患者血清CA125Ⅱ检测的临床意义

江旭; 于仁波; 曾磊

doi:10.3971/j.issn.1000-8578.1071

肺癌患者血清CA125Ⅱ检测的临床意义

The Clinical Value of Serum CA125Ⅱ in Lung Cancer Patients

摘要

摘要: 目的　探讨CA125Ⅱ检测对肺癌的辅助诊断和疗效观察的价值。方法　采用IRMA法，对90例肺癌患者和20例肺良性疾病患者血清CA125Ⅱ检测。结果　各组肺癌CA125Ⅱ水平均显著高于肺良性疾患组和正常对照组(P＜0.05及P＜0.01)；其阳性检出率分别是鳞癌36.1%，腺癌71.4%，未分化癌41.7%，对整体肺癌的敏感性为53.3%，特异性为95.0%，其阳性检出率与临床分期有关，Ⅲ、Ⅳ期明显高于Ⅰ、Ⅱ期(P＜0.01)。结论　CA125Ⅱ测定对肺癌特别是肺腺癌的诊断有较高的价值，是临床分期，疗效观察以及预后判断的重要参考指标。

Abstract: Objective To investigate the clinical value of serum CA125Ⅱ in lung cancer patients. Methods The serum CA125Ⅱ level of 90 lung cancer and 20 lung benign disease patients were tested by immunoradiometoric assay( IRMA). Results The serum CA125Ⅱ level of lung cancer patients was significantly higher than those of lung benign disease and normal control group patients (P＜0.05 or P＜0.01).Among the total,the CA125Ⅱ positive rate in the cases of squamous,adenoild and undifferinated carcinoma were 36.1%，71.4% and 41.7% respectively.The diagnostic sensitivity and specificity of serum CA125Ⅱ for lung cancer were 53.3% and 95.0% respectively.The serum CA125Ⅱ level was significantly reference with clinical stages.The positive rate of Ⅲ,Ⅳ stage was significantly higher than that of Ⅰ,Ⅱ stage (P＜0.01). Conclusion The determination of serum CA125Ⅱ for the lung cancer,especially adenocarcinoma,is a useful diagnosis method.It can be used as an adjunctive test in the clinical stages,observation of result and judgement of prognosis.

HTML全文

参考文献(0)

施引文献

资源附件(0)